Yazar "Eslam, Mohammed" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim
    Yayın
    Dual etiology vs. MetALD: how MAFLD and MASLD address liver diseases coexistence
    (OAE Publishing, 2025) Zerehpooshnesfchi, Shadi; Lonardo, Amedeo; Fan, Jian-Gao; Elwakil, Reda; Tanwandee, Tawesak; Altarrah, Munira; Örmeci, Necati; Eslam, Mohammed
    Fatty liver disease associated with metabolic dysfunction has emerged as a significant global health challenge. This condition often coexists with other liver diseases, such as alcohol-related liver disease and viral hepatitis, complicating both diagnosis and management. To address the limitations of the non-alcoholic fatty liver disease (NAFLD) classification, two alternative frameworks have been proposed: metabolic dysfunction-associated fatty liver disease (MAFLD) in 2020 and metabolic dysfunction-associated steatotic liver disease (MASLD) in 2023. A key difference between these definitions is how they consider fatty liver disease in relation to the coexistence of other liver conditions. MAFLD adopts a dual etiology concept, creating a unified classification system that aligns with contemporary clinical and epidemiological needs. In contrast, MASLD introduces a new term, MetALD (metabolic and alcohol-related/associated liver disease), to describe patients who have both metabolic dysfunction and excessive alcohol intake. This review critically examines the clinical, research, and epidemiological implications of the differing approaches of MAFLD and MASLD, offering insights into their potential to enhance the understanding and management of multi-etiology liver diseases.
  • Küçük Resim
    Yayın
    MAFLD: A comprehensive review of the link between metabolic dysfunction and cardiovascular risk
    (Taylor & Francis, 2025) M. Mostafa, Alaa; Pan, Ziyan; Yu, Ming-Lung; Örmeci, Necati; Fouad, Yasser; Eslam, Mohammed
    Metabolic dysfunction-associated fatty liver disease (MAFLD) affects over 30% of the global population. It is a multisystem condition with a strong association with cardiovascular disease (CVD), the leading cause of mortality worldwide. Key shared mechanisms, including insulin resistance, systemic inflammation, oxidative stress, and genetic predisposition, couple MAFLD with increased risks of coronary artery disease, ischemic heart disease, and heart failure. Early detection via non-invasive imaging and biomarkers is crucial for effective risk stratification. Management strategies emphasize lifestyle modifications and the development of targeted pharmacotherapies addressing metabolic and inflammatory pathways. Understanding the interconnected pathogenic mechanisms facilitates personalized interventions to reduce morbidity and improve long-term outcomes. A multidisciplinary approach remains essential to prevent and manage the cardiovascular implications of MAFLD.
  • Küçük Resim
    Yayın
    The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease
    (Springer, 2025) Eslam, Mohammed; Fan, Jian-Gao; Yu, Ming-Lung; Wong, Vincent Wai-Sun; Cua, Ian Homer; Liu, Chun-Jen; Tanwandee, Tawesak; Örmeci, Necati; K. Sarin, Shiv; George, Jacob
    Metabolic dysfunction-associated fatty liver disease (MAFLD) affects over one-fourth of the global adult population and is the leading cause of liver disease worldwide. To address this, the Asian Pacific Association for the Study of the Liver (APASL) has created clinical practice guidelines focused on MAFLD. The guidelines cover various aspects of the disease, such as its epidemiology, diagnosis, screening, assessment, and treatment. The guidelines aim to advance clinical practice, knowledge, and research on MAFLD, particularly in special groups. The guidelines are designed to advance clinical practice, to provide evidence-based recommendations to assist healthcare stakeholders in decision-making and to improve patient care and disease awareness. The guidelines take into account the burden of clinical management for the healthcare sector.